Business Context and Reporting Period
Gossamer Bio, Inc. (Nasdaq: GOSS), an emerging growth company incorporated in Delaware, filed this Form 8-K on May 2, 2019. The filing reports the entry into a material definitive agreement and the creation of a direct financial obligation effective as of the closing date, May 2, 2019.
Key Financial Metrics and Debt Structure
The Company entered into a Credit Facility with MidCap Financial Trust and additional lenders (including affiliates of Silicon Valley Bank) to fund working capital and general business purposes.
- Total Commitment: Up to $150.0 million in term loans.
- Initial Funding: $30.0 million funded at closing.
- Remaining Tranches: $120.0 million available in three tranches ($40.0 million, $30.0 million, and $50.0 million) subject to clinical milestones, minimum cash requirements, and specific availability windows between 2020 and 2021.
- Interest Rate: One-month LIBOR (with a 2.00% floor) plus 6.15%.
- Repayment Terms: Interest-only payments until June 1, 2021. Amortization begins June 1, 2021, over 36 months (or until maturity on May 1, 2024 for later tranches).
- Fees: $1.5 million origination fee paid at closing. Exit fee of 1.75% upon final repayment. Prepayment fees range from 3.0% to 1.0% depending on the timing of prepayment.
- Collateral: Secured by substantially all personal property, including intellectual property, and equity interests in subsidiaries.
Material Changes and Covenants
This filing represents a significant change in the Company's capital structure, introducing substantial debt obligations where none were previously detailed in this context. Key covenants include:
- Minimum Cash Covenant: Credit Parties must maintain unrestricted cash equal to at least 25% of the outstanding principal amount of the term loans.
- Negative Covenants: Restrictions on incurring additional indebtedness, mergers, acquisitions, paying dividends, making investments, creating liens, and changes in control.
- Events of Default: Include failure to pay, breach of covenants, insolvency, change in control, certain FDA/regulatory events, delisting from NASDAQ, and material adverse changes.
Outlook, Risks, and Contingencies
The availability of the remaining $120.0 million is contingent upon the achievement of specific clinical development milestones and the maintenance of minimum cash levels. The filing highlights significant risks associated with the debt structure:
- Liquidity Risk: Failure to maintain the 25% minimum cash covenant could trigger an event of default.
- Regulatory Risk: Certain FDA or regulatory events constitute an event of default, which could accelerate debt repayment.
- Default Consequences: An event of default could result in a 3.0% penalty interest rate and allow lenders to exercise remedies, including foreclosure on collateral and cash.
Investor Verification Checklist
- Verify the Company's current unrestricted cash balance against the 25% minimum cash covenant requirement relative to the $30.0 million initial draw.
- Review the specific clinical development milestones required to unlock the $120.0 million in remaining tranches.
- Assess the impact of the 6.15% + LIBOR interest rate and the 1.75% exit fee on future cash flow projections.
- Monitor the Company's status regarding FDA regulatory events and NASDAQ listing compliance to avoid triggering events of default.
- Confirm the status of the $1.5 million origination fee payment and its impact on immediate liquidity.